Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Programmed cell death (PCD) enables cells to co-ordinate their exit to benefit the surviving organism. A new study describes how cells can programme their death by inducing extensive disulfide bonding of the actin cytoskeleton in response to an imbalance of cystine, a raw material for glutathione production.
Activation of a crucial immune adaptor protein, STING, is tightly regulated by subcellular trafficking, but how it is deactivated remains less well defined. A study now shows that ESCRT-dependent encapsulation of STING-carrying vesicles by lysosomal compartments — through the process of microautophagy — mediates the termination of STING signalling.
A study using a multi-organoid platform and state-of-the-art transcriptional profiling identifies potential therapeutic targets against SARS-CoV-2. The authors find that CIART, a gene involved in circadian regulation, promotes SARS-CoV-2 infection by regulating the retinoid X receptor pathway and fatty acid synthesis.
Extracellular matrix (ECM) stiffening is a hallmark of cancer aggressiveness. Diverse ECM environments can alter the number and cargo of small extracellular vesicles (sEVs). Wu et al. now delineate a pathway from ECM stiffness to FAK/PI3K/Akt signalling and Rab8-induced sEV secretion, promoting cancer growth.
An ependymoma subtype is driven by fusion proteins related to the transcriptional regulator YAP1. Research now shows that localization of these fusion proteins within nuclear condensates is necessary and sufficient for tumour formation through the activation of various genetic and epigenetic oncogenic mechanisms.
Extramitochondrial coenzyme Q (CoQ) can function as a potent anti-ferroptosis radical trapper. However, it is largely unknown how CoQ is transported from mitochondria to the plasma membrane. A study now suggests that PARL-mediated STARD7 processing is responsible for the cellular distribution of CoQ.
Tight regulation of the activity of EWS–ETS fusion proteins is essential for the growth of Ewing sarcomas. Two new studies show that the transcriptional repressor ETV6 is essential for tumour growth, acting to restrain fusion-protein-mediated gene activation, and revealing the importance of tissue-specific transcription factors to oncogenesis.
End-binding proteins attach to the dynamic plus-ends of microtubules in order to regulate microtubule polymerization and the transport of other plus-end tracking proteins (+TIPs). Three new studies dissect the multivalent interactions that constitute distinct +TIP networks and reveal that they give rise to liquid-like biomolecular condensates.
The bone marrow is the daily production site for hundreds of billions of blood cells. A new study adds evidence that, during ageing, signals emanating from bone-marrow stromal cells shift to produce inflammatory factors that skew blood-cell output, driving age-related tissue deterioration.
Tumour-initiating cells are resistant to challenging growth conditions during the initiation of pancreatic cancer, but how transformed cells acquire a stress-resistant, tumour-initiating state remains unclear. Here, the authors identify a signalling cascade in which LPAR4 induces fibronectin production, cancer stemness and a tumour-initiating niche.
Bivalent genes are regulated by a balance between repressive Polycomb group proteins and activating trithorax group proteins. A new study has revealed that MENIN, an accessory component of KMT2A/B methyltransferase complexes, has an unorthodox role in repressing bivalent genes, alongside Polycomb repressive complexes.
PD-1 and PD-L1 are important immune checkpoint molecules that modulate T cell activity. A study now shows that PD-1 marks leukaemia stem cells (LSCs) in T cell acute lymphoblastic leukaemia and reveals therapeutic opportunities to target LSCs via anti-PD-1 therapy.
